SK10982003A3 - Nové použitie - Google Patents

Nové použitie Download PDF

Info

Publication number: SK10982003A3
Authority: SK; Slovakia
Prior art keywords: alkyl; alkoxy; group; halogen; compound
Prior art date: 2001-03-08

Application number

SK1098-2003A

Other languages

English (en)

Slovak (sk)

Inventor

Arne Eek

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-08

Filing date

2002-03-05

Publication date

2004-02-03

2001-03-08 Priority claimed from SE0100798A external-priority patent/SE0100798D0/xx

2001-10-03 Priority claimed from SE0103291A external-priority patent/SE0103291D0/xx

2002-03-05 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2004-02-03 Publication of SK10982003A3 publication Critical patent/SK10982003A3/sk

Links

229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims abstract description 54
239000003814 drug Substances 0.000 claims abstract description 45
208000007107 Stomach Ulcer Diseases 0.000 claims abstract description 34
150000001875 compounds Chemical class 0.000 claims abstract description 34
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims abstract description 34
230000002265 prevention Effects 0.000 claims abstract description 24
229940122361 Bisphosphonate Drugs 0.000 claims abstract description 21
229940111134 coxibs Drugs 0.000 claims abstract description 20
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims abstract description 20
150000004663 bisphosphonates Chemical class 0.000 claims abstract description 19
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
241000124008 Mammalia Species 0.000 claims abstract description 9
150000003839 salts Chemical class 0.000 claims abstract description 8
239000002552 dosage form Substances 0.000 claims abstract description 3
-1 3-trifluoromethylphenylmethyl Chemical group 0.000 claims description 27
229940079593 drug Drugs 0.000 claims description 27
229910052736 halogen Inorganic materials 0.000 claims description 21
150000002367 halogens Chemical class 0.000 claims description 18
238000004519 manufacturing process Methods 0.000 claims description 15
229910052739 hydrogen Inorganic materials 0.000 claims description 14
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 12
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
125000003118 aryl group Chemical group 0.000 claims description 8
239000001257 hydrogen Substances 0.000 claims description 8
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
125000001424 substituent group Chemical group 0.000 claims description 8
229910052760 oxygen Inorganic materials 0.000 claims description 7
238000002560 therapeutic procedure Methods 0.000 claims description 7
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 6
239000003085 diluting agent Substances 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 6
125000002883 imidazolyl group Chemical group 0.000 claims description 6
125000001041 indolyl group Chemical group 0.000 claims description 6
125000001624 naphthyl group Chemical group 0.000 claims description 6
125000004076 pyridyl group Chemical group 0.000 claims description 6
125000000217 alkyl group Chemical group 0.000 claims description 5
125000005843 halogen group Chemical group 0.000 claims description 5
239000008203 oral pharmaceutical composition Substances 0.000 claims description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 4
239000001301 oxygen Substances 0.000 claims description 4
229910052794 bromium Inorganic materials 0.000 claims description 3
229910052799 carbon Inorganic materials 0.000 claims description 3
229910052801 chlorine Inorganic materials 0.000 claims description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
229910052731 fluorine Inorganic materials 0.000 claims description 3
125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 2
125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 claims description 2
125000006017 1-propenyl group Chemical group 0.000 claims description 2
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 claims description 2
125000006022 2-methyl-2-propenyl group Chemical group 0.000 claims description 2
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
125000004432 carbon atom Chemical group C* 0.000 claims description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
125000004093 cyano group Chemical group *C#N 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
125000002757 morpholinyl group Chemical group 0.000 claims description 2
125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 2
SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 2
229910052717 sulfur Inorganic materials 0.000 claims description 2
150000002431 hydrogen Chemical class 0.000 claims 3
125000003545 alkoxy group Chemical group 0.000 claims 2
229910052757 nitrogen Inorganic materials 0.000 claims 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
238000011282 treatment Methods 0.000 abstract description 15
201000005917 gastric ulcer Diseases 0.000 abstract description 7
VNHBYKHXBCYPBJ-UHFFFAOYSA-N 5-ethynylimidazo[1,2-a]pyridine Chemical class C#CC1=CC=CC2=NC=CN12 VNHBYKHXBCYPBJ-UHFFFAOYSA-N 0.000 description 18
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 12
YTJAMOLQXDNLJC-UHFFFAOYSA-N N1N=CC=C2N=CC=C21 Chemical class N1N=CC=C2N=CC=C21 YTJAMOLQXDNLJC-UHFFFAOYSA-N 0.000 description 9
208000025865 Ulcer Diseases 0.000 description 8
150000003230 pyrimidines Chemical class 0.000 description 8
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 7
230000008901 benefit Effects 0.000 description 7
150000005234 imidazo[1,2-a]pyridines Chemical class 0.000 description 7
239000000203 mixture Substances 0.000 description 7
238000011321 prophylaxis Methods 0.000 description 7
IDSZXCFCCNVXER-UHFFFAOYSA-N 8-[(2-ethyl-6-methylphenyl)methylamino]-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide Chemical compound CCC1=CC=CC(C)=C1CNC1=CC(C(N)=O)=CN2C1=NC(C)=C2C IDSZXCFCCNVXER-UHFFFAOYSA-N 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
229960000905 indomethacin Drugs 0.000 description 6
210000002784 stomach Anatomy 0.000 description 6
231100000397 ulcer Toxicity 0.000 description 6
208000001132 Osteoporosis Diseases 0.000 description 5
230000009286 beneficial effect Effects 0.000 description 5
230000000694 effects Effects 0.000 description 5
210000001035 gastrointestinal tract Anatomy 0.000 description 5
229910052740 iodine Inorganic materials 0.000 description 5
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
208000034578 Multiple myelomas Diseases 0.000 description 4
206010035226 Plasma cell myeloma Diseases 0.000 description 4
206010003246 arthritis Diseases 0.000 description 4
230000002496 gastric effect Effects 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
229940126409 proton pump inhibitor Drugs 0.000 description 4
239000000612 proton pump inhibitor Substances 0.000 description 4
230000002195 synergetic effect Effects 0.000 description 4
208000002193 Pain Diseases 0.000 description 3
238000011260 co-administration Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
125000004435 hydrogen atom Chemical class [H]* 0.000 description 3
230000006698 induction Effects 0.000 description 3
208000027866 inflammatory disease Diseases 0.000 description 3
230000002757 inflammatory effect Effects 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 3
229960000620 ranitidine Drugs 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 2
DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 2
206010059024 Gastrointestinal toxicity Diseases 0.000 description 2
MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 2
102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 2
108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 2
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 2
IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 2
DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 2
229940062527 alendronate Drugs 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
230000001120 cytoprotective effect Effects 0.000 description 2
229940009626 etidronate Drugs 0.000 description 2
231100000414 gastrointestinal toxicity Toxicity 0.000 description 2
229940015872 ibandronate Drugs 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 2
229960000381 omeprazole Drugs 0.000 description 2
WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 2
229940046231 pamidronate Drugs 0.000 description 2
230000037361 pathway Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
229940089617 risedronate Drugs 0.000 description 2
RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 2
229940019375 tiludronate Drugs 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 2
229960004276 zoledronic acid Drugs 0.000 description 2
RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
GUHPRPJDBZHYCJ-SECBINFHSA-N (2s)-2-(5-benzoylthiophen-2-yl)propanoic acid Chemical compound S1C([C@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-SECBINFHSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
231100000699 Bacterial toxin Toxicity 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
206010065687 Bone loss Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
206010006811 Bursitis Diseases 0.000 description 1
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
208000034656 Contusions Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
APQPGQGAWABJLN-UHFFFAOYSA-N Floctafenine Chemical compound OCC(O)COC(=O)C1=CC=CC=C1NC1=CC=NC2=C(C(F)(F)F)C=CC=C12 APQPGQGAWABJLN-UHFFFAOYSA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
208000007882 Gastritis Diseases 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
208000037147 Hypercalcaemia Diseases 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
208000037848 Metastatic bone disease Diseases 0.000 description 1
229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitrogen oxide(NO) Natural products O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
206010030201 Oesophageal ulcer Diseases 0.000 description 1
208000010191 Osteitis Deformans Diseases 0.000 description 1
208000003076 Osteolysis Diseases 0.000 description 1
208000027868 Paget disease Diseases 0.000 description 1
102100032709 Potassium-transporting ATPase alpha chain 2 Human genes 0.000 description 1
108010083204 Proton Pumps Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
208000010040 Sprains and Strains Diseases 0.000 description 1
206010042674 Swelling Diseases 0.000 description 1
208000000491 Tendinopathy Diseases 0.000 description 1
206010043255 Tendonitis Diseases 0.000 description 1
208000008312 Tooth Loss Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
229940069428 antacid Drugs 0.000 description 1
239000003159 antacid agent Substances 0.000 description 1
230000001458 anti-acid effect Effects 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
239000000688 bacterial toxin Substances 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229940047495 celebrex Drugs 0.000 description 1
229960000590 celecoxib Drugs 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
229960001259 diclofenac Drugs 0.000 description 1
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
229960000616 diflunisal Drugs 0.000 description 1
HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
208000000718 duodenal ulcer Diseases 0.000 description 1
230000001856 erectile effect Effects 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
229960005293 etodolac Drugs 0.000 description 1
XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
229960001419 fenoprofen Drugs 0.000 description 1
229960003240 floctafenine Drugs 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229960002390 flurbiprofen Drugs 0.000 description 1
SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
238000009472 formulation Methods 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
230000027119 gastric acid secretion Effects 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
230000000148 hypercalcaemia Effects 0.000 description 1
208000030915 hypercalcemia disease Diseases 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
208000028774 intestinal disease Diseases 0.000 description 1
239000011630 iodine Substances 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
229960000991 ketoprofen Drugs 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
230000007787 long-term memory Effects 0.000 description 1
208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
208000027202 mammary Paget disease Diseases 0.000 description 1
229940013798 meclofenamate Drugs 0.000 description 1
HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
229960001929 meloxicam Drugs 0.000 description 1
238000000034 method Methods 0.000 description 1
244000005700 microbiome Species 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229960004270 nabumetone Drugs 0.000 description 1
229960002009 naproxen Drugs 0.000 description 1
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
229960002739 oxaprozin Drugs 0.000 description 1
OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
230000004526 pharmaceutical effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
229960002895 phenylbutazone Drugs 0.000 description 1
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
229960002702 piroxicam Drugs 0.000 description 1
150000003222 pyridines Chemical class 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
229960000371 rofecoxib Drugs 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000000126 substance Substances 0.000 description 1
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
229960000894 sulindac Drugs 0.000 description 1
230000008961 swelling Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
201000004415 tendinitis Diseases 0.000 description 1
229960002871 tenoxicam Drugs 0.000 description 1
WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229960001312 tiaprofenic acid Drugs 0.000 description 1
229960001017 tolmetin Drugs 0.000 description 1
UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
229940087652 vioxx Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK1098-2003A 2001-03-08 2002-03-05 Nové použitie SK10982003A3 (sk)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
SE0100798A SE0100798D0 (sv)	2001-03-08	2001-03-08	New use
SE0103291A SE0103291D0 (sv)	2001-10-03	2001-10-03	New use
PCT/SE2002/000375 WO2002069968A1 (en)	2001-03-08	2002-03-05	New use

Publications (1)

Publication Number	Publication Date
SK10982003A3 true SK10982003A3 (sk)	2004-02-03

Family

ID=26655407

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1098-2003A SK10982003A3 (sk)	2001-03-08	2002-03-05	Nové použitie

Country Status (15)

Country	Link
US (2)	US20040082605A1 (cs)
EP (1)	EP1370261A2 (cs)
JP (1)	JP2004520422A (cs)
KR (1)	KR100904599B1 (cs)
CN (1)	CN1496259A (cs)
BG (1)	BG108144A (cs)
BR (1)	BR0207762A (cs)
CA (1)	CA2440100A1 (cs)
CZ (1)	CZ20032398A3 (cs)
EE (1)	EE05234B1 (cs)
IL (1)	IL157461A0 (cs)
MX (1)	MXPA03007888A (cs)
NO (1)	NO20033919L (cs)
SK (1)	SK10982003A3 (cs)
WO (1)	WO2002069968A1 (cs)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6852739B1 (en)	1999-02-26	2005-02-08	Nitromed Inc.	Methods using proton pump inhibitors and nitric oxide donors
AU2003254282A1 (en) *	2002-08-01	2004-02-23	Nitromed, Inc.	Nitrosated proton pump inhibitors, compositions and methods of use
WO2004026867A2 (en) *	2002-09-19	2004-04-01	Schering Corporation	Imidazopyridines as cyclin dependent kinase inhibitors
KR20050072090A (ko) *	2002-09-19	2005-07-08	쉐링 코포레이션	사이클린 의존성 키나제 억제제로서의 피라졸로피리딘
BRPI0407541A (pt) *	2003-02-17	2006-02-14	Altana Pharma Ag	combinações e uso de compostos farmaceuticamente ativos selecionados
JPWO2011102460A1 (ja) *	2010-02-19	2013-06-17	学校法人関西医科大学	胃潰瘍の予防又は治療剤、経口投与薬、及び胃潰瘍の予防又は治療剤の製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT290523B (de) *	1962-01-05	1971-06-11	Merck & Co Inc	Verfahren zur Herstellung neuer α-(3-Indolyl)-carbonsäuren
ZA81219B (en) *	1980-01-23	1982-01-27	Schering Corp	Imidazo (1,2-a) pyridines ,process for their preparation and pharmaceutical compositions containing them
EP0068378B1 (en) *	1981-06-26	1986-03-05	Schering Corporation	Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them
DE3922387A1 (de) *	1989-07-07	1991-01-17	Kali Chemie Pharma Gmbh	N-benzyl-n-((1s,5s)-6,6-dimethylbicyclo/3.1.1/hept-2-ylaethoxy-aethyl)-morpholinium-salze enthaltende gastroprotektiv wirksame pharmazeutische zubereitungen
IN171746B (cs) *	1989-11-02	1992-12-26	Mcneil Ppc Inc
KR920002148A (ko) *	1990-07-03	1992-02-28	안드레아 엘. 콜비	비스테로이드계 소염제에 의해 유발된 위장 증상을 완화시키기 위한 약제 조성물 및 이를 완화시키는 방법
DK0550083T3 (da) *	1991-12-06	1999-10-11	Glaxo Group Ltd	Lægemidler til behandling af inflammatoriske tilstande eller til analgesi og indeholdende et NSAID og ranitidinbismuthcitra
HUP0001555A3 (en) *	1997-10-30	2001-01-29	Altana Pharma Ag	Tetrahydro-imidazo-naphthyridine derivatives, pharmaceutical compositions thereof and process for their preparation
SE9801526D0 (sv) *	1998-04-29	1998-04-29	Astra Ab	New compounds
WO2000017200A1 (en) *	1998-09-23	2000-03-30	Byk Gulden Lomberg Chemische Fabrik Gmbh	Tetrahydropyridoethers
AU3966600A (en) *	1999-04-17	2000-11-02	Byk Gulden Lomberg Chemische Fabrik Gmbh	Haloalkoxy imidazonaphthyridines

2002
- 2002-03-05 CZ CZ20032398A patent/CZ20032398A3/cs unknown
- 2002-03-05 JP JP2002569143A patent/JP2004520422A/ja active Pending
- 2002-03-05 IL IL15746102A patent/IL157461A0/xx unknown
- 2002-03-05 KR KR1020037011676A patent/KR100904599B1/ko not_active Expired - Fee Related
- 2002-03-05 CA CA002440100A patent/CA2440100A1/en not_active Abandoned
- 2002-03-05 WO PCT/SE2002/000375 patent/WO2002069968A1/en not_active Ceased
- 2002-03-05 CN CNA028061098A patent/CN1496259A/zh active Pending
- 2002-03-05 BR BR0207762-0A patent/BR0207762A/pt not_active IP Right Cessation
- 2002-03-05 MX MXPA03007888A patent/MXPA03007888A/es not_active Application Discontinuation
- 2002-03-05 SK SK1098-2003A patent/SK10982003A3/sk not_active Application Discontinuation
- 2002-03-05 EP EP02701851A patent/EP1370261A2/en not_active Withdrawn
- 2002-03-05 US US10/469,906 patent/US20040082605A1/en not_active Abandoned
- 2002-03-05 EE EEP200300434A patent/EE05234B1/xx not_active IP Right Cessation
2003
- 2003-09-01 BG BG108144A patent/BG108144A/xx unknown
- 2003-09-04 NO NO20033919A patent/NO20033919L/no not_active Application Discontinuation
2008
- 2008-08-04 US US12/185,514 patent/US20090170854A1/en not_active Abandoned

Also Published As

Publication number	Publication date
BR0207762A (pt)	2004-06-01
CN1496259A (zh)	2004-05-12
EP1370261A2 (en)	2003-12-17
EE05234B1 (et)	2009-12-15
WO2002069968A8 (en)	2003-04-17
EE200300434A (et)	2003-12-15
CZ20032398A3 (cs)	2004-02-18
JP2004520422A (ja)	2004-07-08
KR100904599B1 (ko)	2009-06-25
KR20040007461A (ko)	2004-01-24
CA2440100A1 (en)	2002-09-12
US20040082605A1 (en)	2004-04-29
BG108144A (en)	2004-09-30
US20090170854A1 (en)	2009-07-02
NO20033919D0 (no)	2003-09-04
MXPA03007888A (es)	2003-12-04
IL157461A0 (en)	2004-03-28
NO20033919L (no)	2003-09-04
WO2002069968A1 (en)	2002-09-12

Legal Events

Date	Code	Title	Description
2010-10-07	FC9A	Refused patent application

Publication	Publication Date	Title
AU2014372166B2 (en)	2017-10-26	Pharmaceutical combinations
RU2325913C2 (ru)	2008-06-10	Применение золедроновой кислоты, ее солей, гидратов и способ антиноцицептивного или антиаллодинического лечения боли, способ лечения невропатической боли
SK17392001A3 (sk)	2002-07-02	Použitie zlúčenín ako antibakteriálnych činidiel
US20090170854A1 (en)	2009-07-02	New Use
RU2331646C2 (ru)	2008-08-20	Новые соединения
RU2000113729A (ru)	2002-04-27	Гетероциклические соединения для ингибирования секреции желудочной кислоты, способы их получения и их фармацевтические компоозиции
CN100376245C (zh)	2008-03-26	结合有泰妥拉唑与消炎剂的药物组合物
IL175716A (en)	2015-05-31	2- (4-Bromo- or 4-Methyl-Phenylamino) -6-Oxo-1,6-Dihydropyridines and their use in drug preparation
SK280283B6 (sk)	1999-11-08	Farmaceutický prostriedok na liečenie žalúdočných
JP3479780B2 (ja)	2003-12-15	骨吸収を抑制する方法
JP2024169669A (ja)	2024-12-05	腔内適用による結直腸がんの細菌プロモーターを排除するための組成物
RU2004103475A (ru)	2005-06-10	Производные арил-или гетероарилазолилкарбинолов для лечения недержания мочи
JP2004521150A5 (cs)	2005-10-06
US10898501B2 (en)	2021-01-26	Combination therapy effective against microorganisms, including drug resistant microorganisms
US8623864B2 (en)	2014-01-07	Thioridazine and derivatives thereof for reversing anti-microbial drug-resistance
AU2002235080A1 (en)	2002-09-19	New use
GB2590341A (en)	2021-06-23	Storage stable somatostatin-dopamine chimeric compounds and salt forms thereof
JP2010523470A (ja)	2010-07-15	抗癌化合物の投与方法
RU2006123423A (ru)	2008-01-20	Фармацевтические применения бисфосфонатов
JP2007513118A5 (cs)	2008-01-24
KR20040078118A (ko)	2004-09-08	치환된 아크릴로일 디스타마이신 유도체 및 단백질 키나제(세린/트레오닌 키나제) 저해제를 포함하는 항종양 조합요법
RU2009128186A (ru)	2011-01-27	Производные трициклических аминов в качестве ингибиторов тирозинкиназы
KR20050100671A (ko)	2005-10-19	이미다조피리딘 함유 조합물, 및 위장관 염증성 질환 치료시의 이의 용도
TH2101004640A (th)	2026-01-19	วงแหวนที่มี 5 สมาชิกแบบ n-เฮทเทอโรไซคลิกที่มีตัวยับยั้งการรวมกันของโปรตีนแคปสิด, องค์ประกอบทางเภสัชกรรมและการใช้ของสิ่งนั้น
JP2008518015A5 (cs)	2008-11-13